SciBase publishes the Annual report for 2020

SciBase hereby announces that the Annual report for 2020 is available at the Company’s website www.scibase.com.

A pdf-version of the annual report is enclosed to this press-release.A printed version of the Annual report will only be distributed to shareholders who actively request a printed copy.
For more information, please contact:

Michael Colérus, CFO

Tel: +46 70 341 34 72

E-mail: michael.colerus@scibase.com

Certified Advisor

Avanza

Tel: +46 8 409 421 20

E-mail: ca@avanza.se

The information was submitted for publication, through the agency of the contact person set out above, at 09.00 CET on April 9, 2021.

About SciBase and Nevisense

SciBase AB is a global medical technology company based in Stockholm, Sweden that develops unique point-of-care devices for the evaluation of skin disorders such as skin cancer and atopic dermatitis. SciBase's first product, Nevisense, helps clinicians detect melanoma, the most dangerous type of skin cancer. Further development has led to Nevisense also being used as a tool to assess the skin barrier and non-melanoma skin cancer. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and an FDA approval (PMA) in the United States. SciBase technology is based Electrical Impedance Spectroscopy (EIS) combined with Artificial Intelligence (AI) algorithms that interpret the varying electrical properties of human tissue to detect malignancies and abnormalities. SciBase Holding AB is listed on First North Growth Market ("SCIB"). Further information is available at www.scibase.com.

Tags: